High-Grade Squamous Intraepithelial Lesions Clinical Trial
Official title:
Association Between Surgical Timing and Route of Total Hysterectomy After Loop Electrosurgical Excision Procedure and Perioperative Risk in Patients With Cervical High-grade Squamous Intraepithelial Lesion
| Verified date | March 2024 |
| Source | Sichuan Cancer Hospital and Research Institute |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This study aimed to analyze perioperative information in patients with high-grade squamous intraepithelial lesion (HSIL) undergoing total hysterectomy (TH), offering insights into optimal surgery timing, selecting the operation path, and enhancing surgical operation details.
| Status | Completed |
| Enrollment | 826 |
| Est. completion date | March 1, 2024 |
| Est. primary completion date | March 1, 2024 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: - patients were confirmed with HSIL through pathology at our hospital or another tertiary facility, with additional confirmation via pathological consultation at our facility; - LH or abdominal hysterectomy (AH) +/- bilateral fallopian tube or bilateral adnexectomy was performed after LEEP; - the patient had no history of systemic malignancies. Exclusion Criteria: - severe medical and surgical complications; - an extensive or subextensive hysterectomy was performed; - surgical removal scope involving tissues (such as lymph nodes) or organs (such as the appendix) other than the uterus, ovaries, and fallopian tubes; - fever symptoms within the last month; - incidence of pelvic and abdominal infections, vaginitis, or similar conditions within the past month. |
| Country | Name | City | State |
|---|---|---|---|
| China | Sichuan Cancer Hospital and Research Institute | Chengdu | Sichuan |
| Lead Sponsor | Collaborator |
|---|---|
| Sichuan Cancer Hospital and Research Institute |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Postoperative fever | Use a thermometer to measure your temperature | Within 7 days of surgery | |
| Primary | Postoperative therapeutic use of antibiotics | Postoperative therapeutic use of antibiotics | Within 7 days of surgery | |
| Secondary | Postoperative complications | Postoperative complications | Within 7 days of surgery | |
| Secondary | Postoperative hospitalization days | Postoperative hospitalization days | Date of surgery to date of discharge | |
| Secondary | Postoperative hemoglobin | Postoperative hemoglobin | Within 7 days of surgery | |
| Secondary | Postoperative white blood cell count | Postoperative white blood cell count | Within 7 days of surgery | |
| Secondary | Postoperative erythrocyte count | Postoperative erythrocyte count | Within 7 days of surgery | |
| Secondary | Postoperative albumin number | Postoperative albumin number | Within 7 days of surgery | |
| Secondary | Postoperative CRP value | Postoperative CRP value | Within 7 days of surgery |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04177641 -
Evaluation of Thioldisulfide Balance in Cervical Preinvasive Lesions
|
||
| Recruiting |
NCT05210348 -
Clinical Evaluation of Detection of High Risk HPV in Urine
|
||
| Not yet recruiting |
NCT04115787 -
Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN
|
||
| Active, not recruiting |
NCT02576561 -
Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL
|
Phase 2 | |
| Active, not recruiting |
NCT05613283 -
Primary Cervical Cancer Screening by Self-sampling HPV Test
|
||
| Not yet recruiting |
NCT06333743 -
Laser Ablation in the Treatment of High-grade Cervical Lesions
|
N/A | |
| Completed |
NCT03920800 -
Preventing Invasive Cervical Cancer: The Importance of Expectant Management in Young Women With High-grade Pre-cancerous Lesions
|
||
| Completed |
NCT03239223 -
Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection
|
Phase 1 | |
| Not yet recruiting |
NCT06233331 -
Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV
|
Phase 1 |